28 de julio de 2016 / 6:59 / hace un año

BRIEF-Merck & Co and AmoyDx collaborate to bring liquid biopsy RAS biomarker testing to China

July 28 (Reuters) - Merck & Co Inc :

* Merck and AmoyDx collaborate to bring liquid biopsy RAS biomarker testing to China

* Merck and AmoyDx plan to implement ADX-SuperARMS liquid biopsy RAS test in Chinese medical centers in 2017

* Plan to expand into other markets such as Argentina, India, Mexico, Taiwan, Hong Kong, Brazil, and Russia by 2019

* Test will be developed using AmoyDx real-time polymerase chain reaction technology,ADX-SuperARMS,will be made available in China in 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below